Alejandro González Veliz: Balancing Ischemic Protection and Bleeding Risk in Antiplatelet Management
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn about a recent article by Craig J. Beavers et al., published in Circulation, adding:
“Antiplatelet therapy is more than choosing a drug. It is about getting the entire strategy right.
The 2026 AHA Scientific Statement on multidisciplinary antiplatelet management highlights a central challenge in coronary care:
Balancing ischemic protection against bleeding risk while ensuring that treatment remains appropriate and uninterrupted.
Key clinical takeaways:
- DAPT duration should reflect the clinical presentation, bleeding risk and thrombotic risk.
- Shorter DAPT may be appropriate for selected patients, but the evidence should be interpreted cautiously in those at high ischemic risk.
- Nonadherence and unintended treatment interruption remain important, potentially preventable problems.
- De-escalation, concomitant anticoagulation and perioperative management require careful planning.
- Pharmacists, nurses, cardiologists and patients all contribute to safer long-term treatment.
The goal is not simply to prescribe antiplatelet therapy. It is to deliver the right treatment, to the right patient, for the right duration — with a plan that continues beyond hospital discharge.
How does your team approach antiplatelet reassessment and medication continuity after PCI?”
Title: Multidisciplinary Approach to Antiplatelet Management in Coronary Syndromes: A Scientific Statement From the American Heart Association
Authors: Craig J. Beavers, Paul P. Dobesh, Mary Cushman, Robert J. DiDomenico, Nkechinyere Ijioma, Ravi V. Joshi, Jonathan Medina-Beckwith, Naveen Pereira, Marc Ruel, Rachel G. Tabak
Other posts featuring Alejandro González Veliz on Hemostasis Today.
-
Oct 31, 2026, 19:40Andreas Calatzis: Revisiting a Widely Cited Study on Preoperative Screening for Primary Hemostasis Disorders
-
Oct 31, 2026, 19:40How Antiseizure Medication Selection May Influence DOAC Safety in Epilepsy – JAMA Neurology
-
Oct 31, 2026, 19:29Sascha David: Therapeutic Plasma Exchange Associated with Lower 90 Day Mortality in Streptococcal Septic Shock
-
Oct 31, 2026, 19:25Jessica Garcia: Real-World Evidence on Efanesoctocog Alfa Prophylaxis in Pediatric Hemophilia A
-
Oct 31, 2026, 19:21Cedric Hermans: What If Higher Plasma FIX Levels Do Not Necessarily Mean better Haemostatic Protection?
-
Oct 31, 2026, 19:16Valance Washington: Celebrating Sravya Nimmala’s Outstanding Abstract Award
-
Oct 31, 2026, 16:41Ward Faisal: Ferric Carboxymaltose as an Alternative to Traditional Iron Preparations for Anemia
-
Oct 31, 2026, 16:35Bhavna Daryani: Using Technology to Make Anemia Screening More Accessible and Non-Invasive
-
Oct 31, 2026, 16:33Greg Jackson: Key Insights from the 22nd Annual McMaster Hematology and Thromboembolism Update